ArticleZhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences2025
[Kaempferol in improving chemotherapy-induced myelosuppression: A scoping review].
Article in Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectivesChemotherapy-induced myelosuppression (CIM) is a common and serious adverse reaction during chemotherapy in patients with malignant tumors. Kaempferol, an important active component of leukocyte-elevating traditional Chinese medicine, may play a role in its improvement. This study aims to explore the research status and mechanisms of kaempferol in improving CIM and to provide reference evidence for its application in the prevention and treatment of CIM.
methodsChinese and English literature on kaempferol intervention in CIM was systematically searched in CNKI, WanFang, VIP, PubMed, Web of Science, and Embase databases from database inception to August 8, 2025. Two researchers independently performed literature screening and extracted key information such as study design, intervention measures, and outcome indicators.
resultsA total of 13 eligible studies were included, including 9 animal experimental studies, 1 randomized controlled trial, 2 clinical observational studies, and 1 quasi-experimental study. Existing evidence indicated that kaempferol or compound preparations containing kaempferol increased peripheral blood leukocyte counts to a certain extent and promoted the proliferation of bone marrow nucleated cells. Mechanistic studies suggested that kaempferol exerted bone marrow protective effects through multi-target synergistic actions, including regulation of oxidative stress levels, enhancement of immune function, and inhibition of hematopoietic cell apoptosis.
conclusionsKaempferol shows considerable research potential and certain clinical application prospects in improving CIM. However, existing evidence is still mainly based on traditional Chinese medicine compound preparations and predictive analyses, and high-quality basic research and large-scale clinical studies focusing on kaempferol monotherapy remain insufficient. In the future, rigorously designed empirical studies are needed to further clarify its independent efficacy and mechanisms of action, so as to promote standardized translational application in the prevention and treatment of CIM.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.